Actively Recruiting
A Study to Assess Safety of Teclistamab in Indian Participants With Relapsed and Refractory Multiple Myeloma
Led by Johnson & Johnson Private Limited · Updated on 2026-05-08
75
Participants Needed
12
Research Sites
108 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The purpose of this study is to assess the safety of teclistamab in routine clinical practice when given as monotherapy in Indian participants with relapsed and refractory multiple myeloma (RRMM) (that is, a blood cancer that comes back after treatment or does not respond to treatment) who have previously received at least 3 prior lines of therapy including an immunomodulatory agent, a proteasome inhibitor and an anti-cluster of differentiation (CD)38 antibody (is a protein that fights infection) and whose disease have progressed on the last therapy.
CONDITIONS
Official Title
A Study to Assess Safety of Teclistamab in Indian Participants With Relapsed and Refractory Multiple Myeloma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosed with relapsed and refractory multiple myeloma having received at least 3 prior lines of therapy including a proteasome inhibitor, an anti-CD38 antibody, and an immunomodulatory agent
- Documented disease progression on last therapy based on IMWG response criteria
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2
- Female participants must not be pregnant or breastfeeding and comply with contraceptive requirements according to local regulations
- Women of childbearing potential must have a negative pregnancy test within 24 hours before first treatment dose and use a highly effective contraceptive method during treatment and for 6 months after last dose
You will not qualify if you...
- Not eligible to receive teclistamab as per locally approved prescribing information
- Previous treatment with any BCMA-directed therapy
- Central nervous system involvement or signs of meningeal involvement of multiple myeloma without negative brain MRI and lumbar cytology
- Stroke, transient ischemic attack, or seizure within 6 months before screening
- Major surgery or significant traumatic injury within 2 weeks before enrollment, incomplete recovery from surgery, or planned major surgery during study treatment
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 12 locations
1
M S Ramaiah Medical College and Hospital
Bangalore, India, 560054
Actively Recruiting
2
St. Johns Medical College And Hospital
Bengaluru, India, 560034
Actively Recruiting
3
Post Graduate Institute of Medical Education And Research PGIMER
Chandigarh, India, 160012
Actively Recruiting
4
Bhagwan Mahaveer Cancer Hospital & Research Centre
Jaipur, India, 302017
Actively Recruiting
5
Tata Medical Center
Kolkata, India, 700156
Actively Recruiting
6
Tata Memorial Hospital
Mumbai, India, 400012
Actively Recruiting
7
KIMS-Kingsway Hospitals
Nagpur, India, 440001
Actively Recruiting
8
All India Institute of Medical Sciences
New Delhi, India, 110029
Actively Recruiting
9
Rajiv Gandhi Cancer Institute & Research Centre
New Delhi, India, 110085
Actively Recruiting
10
Jawaharlal Institute of Postgraduate Medical Education and Research
Puducherry, India, 605006
Actively Recruiting
11
Christian Medical College
Ratnagiri Kilminnal, India, 632517
Actively Recruiting
12
Regional Cancer Centre
Thiruvananthapuram, India, 695011
Actively Recruiting
Research Team
S
Study Contact
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here